Shingles Treatment Market Growth Overview, Facts & Figures, Segmentation, Future Trends and Historical Analysis By 2033

The Global Shingles Treatment Market is estimated to be valued at USD 136.15 Bn in 2026 and is expected to reach USD 260.29 Bn by 2033.

BURLINGAME, CA, UNITED STATES, April 16, 2026 /EINPresswire.com/ -- The Global Shingles Treatment Market is estimated to be valued at USD 136.15 Bn in 2026 and is expected to reach USD 260.29 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033. The global shingles treatment market is experiencing notable growth, driven by rising awareness of the risks and complications associated with shingles, especially among older adults. Increased understanding of preventive measures, particularly the use of effective vaccines such as Shingrix, is playing a key role in reducing disease incidence and supporting market expansion.

Get the Sample Copy of the Report at: https://www.coherentmarketinsights.com/insight/request-sample/9043

Global Shingles Treatment Market Key Takeaways

Vaccines (prophylactic) remain the most sought-after treatment type for shingles, accounting for a market share of 74.3% in 2025.

By route of administration, oral segment accounted for 45.6% of the global shingles treatment market share in 2025.

Based on age group, adults (50-64 years) segment leads the market with a share of 80.5% in 2025.

North America is expected to lead the global shingles treatment industry, holding a share of 39.3% in 2025. This is mostly due to rising patient pool and growing adoption of shingles vaccines.

Asia Pacific, with an estimated market share of 24.5% in 2025, is anticipated to emerge as a highly lucrative market for shingles treatment manufacturers during the forecast period.

Rising Incidence of Shingles Spearheading Market Growth

Coherent Market Insights’ recent shingles treatment market analysis sheds light on major growth-driving factors shaping the industry. These include rising prevalence of shingles, growing geriatric population, increasing awareness about shingles, expanding healthcare access, and advancements in shingles treatment options.

The incidence of shingles has shown an upward trend in several countries, including the U.S. and China. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), about 1 in 3 people in the United States will develop herpes zoster during their lifetime. This is expected to drive demand for shingles treatments during the forecast period.

Purchase Now Up to 40% Discount on This Premium Report @ https://www.coherentmarketinsights.com/offernew/buy-now/9043

High Treatment Costs and Low Awareness Hampering Market Growth

The global shingles treatment market outlook indicates strong future growth, owing to growing incidence of shingles and rising need for effective shingles treatments. However, high cost of advanced shingles treatments and lack of awareness in some regions might slow down market growth to some extent.

Advanced shingles vaccines, including recombinant zoster vaccines, and antiviral therapies are expensive. This is making them less affordable, especially in low- and middle-income regions, thereby reducing overall shingles treatment market demand. In addition, many individuals, particularly in developing regions, lack understanding about shingles, its complications, and available treatments, leading to delayed diagnosis and underutilization of preventive vaccines and therapies.

Rising Geriatric Population Creating Market Growth Opportunities

Older adults are at a higher risk of developing shingles and related complications such as postherpetic neuralgia (PHN). According to the World Health Organization (WHO), shingles is more common in adults over 50 years of age, and risk increases with age. Rapid growth in the global population aged 50 and older increases demand for effective prevention and treatment options, including vaccines and antiviral therapies.

Emerging Shingles Treatment Market Trends

Growing emphasis on preventive healthcare is a key growth-shaping trend in the shingles treatment market. There is a shift toward preventive strategies, with many countries recommending or subsidizing shingles vaccination as part of adult immunization programs. These policies expand shingles vaccine uptake and drive overall shingles treatment market growth.

Public health campaigns, education on shingles risks, and awareness about the benefits of early diagnosis and vaccination are encouraging more people to seek preventive care and treatment. This is expected to boost shingles treatment market demand during the assessment period.

People and healthcare professionals are also becoming aware of severe shingles complications, such as postherpetic neuralgia (PHN) and neurological issues. This drives early treatment action and preference for comprehensive care options.

Advancements in shingles treatments are supporting herpes zoster treatment market expansion. Companies are striving to develop improved antiviral drugs that reduce severity and duration of outbreaks. Likewise, next-generation vaccines like Shingrix with better efficacy and safety profiles are entering the market. Ongoing research and development of novel therapies and diagnostics enhance overall treatment effectiveness and patient compliance.

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/9043

Analyst’s View

“The global shingles treatment market is expected to grow rapidly during the forecast period, driven by rising geriatric population, increasing incidence of herpes zoster, growing awareness of postherpetic neuralgia, and expanding adoption of preventive vaccines and antiviral therapies,” said a senior analyst at CMI.

Competitor Insights

Key companies in shingles treatment market report:

Merck & Co., Inc.
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Cipla Limited
Abbott Laboratories
Camber Pharmaceuticals
Johnson & Johnson
Eli Lilly and Company
AstraZeneca
Sun Pharmaceutical Industries Ltd.
Vi­atris Inc.
Reddy’s Laboratories Ltd.

Key Developments

In December 2025, Sanofi agreed to buy Dynavax Technologies, a public company that makes vaccines. Dynavax has a marketed adult hepatitis B vaccine and a shingles vaccine candidate in development.

In July 2025, the U.S. FDA approved GSK’s Shingrix in a prefilled syringe presentation. This recombinant zoster vaccine is used for the prevention of shingles. The new format eliminates the need to reconstitute separate vials, making administration easier.

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Raj Shah
Coherent Market Insights Pvt. Ltd.
+1 252-477-1362
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.